-
Mashup Score: 1Myelofibrosis | Blood Cancers Today - 4 day(s) ago
Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which alters the normal production of blood cells. Get the latest research and news.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 3User account | Research To Practice - 4 day(s) ago
Research To Practice requires users to log in to view educational content. All content is available without
Source: www.researchtopractice.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 5
Affaire Jubillar, mort du petit Emile… De plus en plus de voyants, devins ou radiesthésistes s’invitent dans les procédures judiciaires. Policiers et médiums racontent leur drôle de relation, entre parasitage et collaboration fortuite.
Source: www.liberation.frCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 94
Autologous stem-cell transplantation (ASCT) is considered the standard of care for management of younger patients (ie, younger than 65–70 years) with newly diagnosed mantle cell lymphoma in much of the world. Once associated with a poor overall survival (only 2 years in many reports), mantle cell lymphoma has been the subject of increasingly intense investigational therapies over the past two decades. The first European Mantle Cell Lymphoma Network trial, published in 2005, showed that ASCT prolonged time to progression in younger patients with mantle cell lymphoma.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 1Should we teach business literacy to medical trainees? - 5 day(s) ago
Should we integrate business literacy into medical training to better equip future physicians for the demands of their careers and personal lives?
Source: www.kevinmd.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 1
Monday, May 6, 2024, 5:00 PM – 6:00 PM Eastern Time Register for this complimentary event with the “Register Now” button above, which will take you to our Zoom registration page. Join us on Monday, May 6 th for this CME-accredited webinar 5:00 PM – 6:00 PM ET Faculty Matthew D Galsky, MD Professor of Medicine Icahn School of Medicine at Mount Sinai Co-Leader, Bladder Cancer Center of Excellence Associate Director, Translational Research The Tisch Cancer Institute New York, New York Ashish M Kamat, MD,
Source: www.researchtopractice.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 150
Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 148
Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 1Should we teach business literacy to medical trainees? - 6 day(s) ago
Should we integrate business literacy into medical training to better equip future physicians for the demands of their careers and personal lives?
Source: www.kevinmd.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 94
Autologous stem-cell transplantation (ASCT) is considered the standard of care for management of younger patients (ie, younger than 65–70 years) with newly diagnosed mantle cell lymphoma in much of the world. Once associated with a poor overall survival (only 2 years in many reports), mantle cell lymphoma has been the subject of increasingly intense investigational therapies over the past two decades. The first European Mantle Cell Lymphoma Network trial, published in 2005, showed that ASCT prolonged time to progression in younger patients with mantle cell lymphoma.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
Our #myelofibrosis section editor, Douglas Tremblay, MD, of @IcahnMountSinai, highlights some recent studies: ⭐ Subcutaneous sotatercept as treatment for PMF ⭐ The role of splenic irradiation before HSCT ⭐ Results from SIMPLIFY-1 Read more! https://t.co/itdJvXtP30 https://t.co/KAO6TEWXdE